Magnesium-serinate compound and use thereof
The present invention relates to a novel magnesium-serinate compound and the use thereof, and more particularly, to a novel magnesium-serinate compound in which a magnesium atom is chelated to L-serine, and the pharmaceutical use thereof against central nervous system diseases or the like.
1 . A compound of Serine-Mg-Serine or a pharmaceutically acceptable salt, solvate, hydrate or isomer of the compound
wherein the compound has a peak formed at 800 to 1400 cm −1 and lacks a peak formed at 2100 cm −1 in Fourier transform infrared analysis:
wherein the compound exhibits a 1 H NMR peak located at 0.2 ppm upfield from the α-carbon peak and 0.4 to 0.5 ppm upfield from the β-carbon peak of L-serine;
wherein the carbonyl carbon (C═O) resonance of the compound is shifted downfield by 5.556 to 7.509 ppm relative to that of L-serine, and the β-carbon (C—O) resonance is shifted downfield by 2.548 to 3.725 ppm in the 13 C NMR spectrum; and
wherein, for the 1 H and 13 C NMR measurements, 100 mg of the compound is dissolved in 0.7 mL of D 2 O at 298 K.
2 . A pharmaceutical composition for preventing or treating central nervous system diseases, the pharmaceutical composition containing a compound of Serine-Mg-Serine or a pharmaceutically acceptable salt thereof as an active ingredient,
wherein the compound has a peak formed at 800 to 1400 cm −1 and lacks a peak formed at 2100 cm −1 in Fourier transform infrared analysis:
wherein the compound exhibits a 1 H NMR peak located at 0.2 ppm upfield from the α-carbon peak and 0.4 to 0.5 ppm upfield from the β-carbon peak of L-serine;
wherein the carbonyl carbon (C═O) resonance of the compound is shifted downfield by 5.556 to 7.509 ppm relative to that of L-serine, and the β-carbon (C—O) resonance is shifted downfield by 2.548 to 3.725 ppm in the 13 C NMR spectrum; and
wherein, for the 1 H and 13 C NMR measurements, 100 mg of the compound is dissolved in 0.7 mL of D 2 O at 298 K.
3 . The pharmaceutical composition of claim 2 , wherein the central nervous system diseases are selected from the group consisting of cognitive disorder, intellectual disability, microcephaly, epilepsy, neurodevelopmental disorder, dementia, autism spectrum disorder, Down's syndrome, Rett's syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis.
4 . A health functional food for preventing or alleviating central nervous system diseases, the health functional food containing a compound of Serine-Mg-Serine or a pharmaceutically acceptable salt thereof as an active ingredient,
wherein the compound has a peak formed at 800 to 1400 cm −1 and lacks a peak formed at 2100 cm −1 in Fourier transform infrared analysis:
wherein the compound exhibits a 1 H NMR peak located at 0.2 ppm upfield from the α-carbon peak and 0.4 to 0.5 ppm upfield from the β-carbon peak of L-serine;
wherein the carbonyl carbon (C═O) resonance of the compound is shifted downfield by 5.556 to 7.509 ppm relative to that of L-serine, and the β-carbon (C—O) resonance is shifted downfield by 2.548 to 3.725 ppm in the 13 C NMR spectrum; and
wherein, for the 1 H and 13 C NMR measurements, 100 mg of the compound is dissolved in 0.7 mL of D 2 O at 298 K.
5 . The health functional food of claim 4 , wherein the central nervous system diseases are selected from the group consisting of cognitive disorder, intellectual disability, microcephaly, epilepsy, neurodevelopmental disorder, dementia, autism spectrum disorder, Down's syndrome, Rett's syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis.
6 . A feed additive composition comprising a compound of Serine-Mg-Serine or a pharmaceutically acceptable salt thereof as an active ingredient,
wherein the compound has a peak formed at 800 to 1400 cm −1 and lacks a peak formed at 2100 cm −1 in Fourier transform infrared analysis:
wherein the compound exhibits a 1 H NMR peak located at 0.2 ppm upfield from the α-carbon peak and 0.4 to 0.5 ppm upfield from the β-carbon peak of L-serine;
wherein the carbonyl carbon (C═O) resonance of the compound is shifted downfield by 5.556 to 7.509 ppm relative to that of L-serine, and the β-carbon (C—O) resonance is shifted downfield by 2.548 to 3.725 ppm in the 13C NMR spectrum; and
wherein, for the 1 H and 13 C NMR measurements, 100 mg of the compound is dissolved in 0.7 mL of D 2 O at 298 K.
7 . A reagent composition for inhibiting neuronal cell death, the reagent composition containing a compound of Serine-Mg-Serine or a pharmaceutically acceptable salt thereof,
wherein the compound has a peak formed at 800 to 1400 cm −1 and lacks a peak formed at 2100 cm −1 in Fourier transform infrared analysis:
wherein the compound exhibits a 1H NMR peak located at 0.2 ppm upfield from the α-carbon peak and 0.4 to 0.5 ppm upfield from the β-carbon peak of L-serine;
wherein the carbonyl carbon (C═O) resonance of the compound is shifted downfield by 5.556 to 7.509 ppm relative to that of L-serine, and the β-carbon (C—O) resonance is shifted downfield by 2.548 to 3.725 ppm in the 13C NMR spectrum; and
wherein, for the 1 H and 13 C NMR measurements, 100 mg of the compound is dissolved in 0.7 mL of D 2 O at 298 K.